Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate from the National Medical Products Administration for its drug, Ertugliflozin Metformin Extended-Release Tablets (II), indicating a significant advancement in its product portfolio for diabetes treatment [1] Group 1: Drug Approval Details - The drug is a combination formulation of Ertugliflozin and Metformin Hydrochloride, aimed at improving blood sugar control in adult patients with type 2 diabetes who are already receiving treatment with these medications [1] - The company received the acceptance notice for the drug's marketing authorization application in June 2024 and has recently obtained approval from the National Medical Products Administration [1] - The issuance of the drug registration certificate is considered equivalent to passing the consistency evaluation as per national policy regulations [1]

公司已按照《兽药管理条例》《兽药产品批准文号管理办法》等规定的要求取得硫糖铝片兽药产品批准 文号批件，该兽药具备生产上市销售条件。该兽药批准文号的取得可进一步丰富公司产品品类，对推动 宠物用药战略布局、促进公司发展具有积极意义。 子公司动保科技硫糖铝片用于治疗犬胃溃疡、十二指肠溃疡和胃炎。 格隆汇11月28日丨昂利康(002940.SZ)公布,近日，公司子公司浙江昂利康动保科技有限公司收到中华人 民共和国农业农村部核准签发的"硫糖铝片"兽药产品批准文号批件。通用名称：硫糖铝片兽药产品批准 文号，兽药字：111187075。 ...

Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate from the National Medical Products Administration for its drug, Ertugliflozin Metformin Extended-Release Tablets, which is intended for adult patients with type 2 diabetes who are already undergoing treatment with Ertugliflozin and Metformin to improve blood sugar control [1] Group 1 - The drug is specifically designed for adult patients with type 2 diabetes [1] - The approval of the drug registration certificate is equivalent to passing the consistency evaluation [1] - The pharmaceutical industry is characterized by significant uncertainty in drug sales [1]

浙江昂利康制药股份有限公司 关于子公司获得兽药产品批准文号的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002940 证券简称：昂利康 公告编号：2025-099 近日，浙江昂利康制药股份有限公司（以下简称"公司"）子公司浙江昂利 康动保科技有限公司（以下简称"动保科技"）收到中华人民共和国农业农村部 核准签发的"硫糖铝片"兽药产品批准文号批件。现就相关情况公告如下： 一、批件基本信息 | 通用名称 | 硫糖铝片 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 兽药产品批准文号 | 兽药字 111187075 | | | | | | | | 有效期 | 2025 年 月 26 11 | 11 | 日-2030 | 年 | 月 | 25 | 日 | | 含量规格 | 0.5g | | | | | | | | 企业名称 | 浙江昂利康动保科技有限公司 | | | | | | | | 生产地址 | 浙江省绍兴市嵊州市剡湖街道嵊州大道北 | | | | | | 10 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-100 | 药品通用名称 | 恩格列净二甲双胍缓释片（II） | | --- | --- | | 主要成份 | 恩格列净和盐酸二甲双胍 | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 类 3 | | 规格 | 恩格列净 与盐酸二甲双胍 10mg 1000mg | | 受理号 | CYHS2401866 | | 药品批准文号 | 国药准字 H20256037 | | 药品批准文号有效期 | 至 2030 年 11 月 24 日 | | 上市许可持有人 | 名称：浙江昂利康制药股份有限公司 | | | 地址：浙江省嵊州市嵊州大道北 号 1000 | | 生产企业 | 名称：浙江昂利康制药股份有限公司 地址：绍兴市嵊州市嵊州大道北 号 1000 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经 | | | 审查，本品符合药品注册的有关要求，批准注册，发 | | | 给药品注册证书。 | 一、药品基本信息 二、药品的其他相关信息 恩格列净二甲双胍缓释片（II）是恩格列净和盐酸二甲双胍的 ...

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. plans to raise 1.16 billion yuan through a private placement of A-shares to focus on innovative drug research and industrialization projects, marking a significant step in its transformation from generic drugs to innovative drugs in the oncology field [1][4]. Fundraising and Investment - The company intends to issue shares to no more than 35 specific investors, with the entire raised amount allocated to innovative drug research and industrialization projects, including 670 million yuan for research and 490 million yuan for industrialization [1][2]. Research and Development Focus - Anglikang is concentrating on oncology, advancing two core innovative drugs: ALK-N001, which is in phase I clinical trials, and ALK-N002, which is preparing for clinical application. Both drugs utilize a tumor microenvironment-specific activation platform [2][3]. Industrialization Strategy - The company plans to establish a GMP-compliant innovative drug production base in Shaoxing, Zhejiang, which will support clinical sample supply and future commercial production needs, addressing the gap between research and industrialization [2][3]. Competitive Advantage - Anglikang has built a robust innovative drug layout system supported by a skilled team, advanced technology, and a comprehensive quality management system, enhancing its capability to transition from a generic drug company to a modern innovative drug enterprise [3][4]. Financial and Operational Impact - The successful fundraising will significantly increase the company's total assets and net assets, reduce the debt ratio, and enhance its capital structure, thereby improving its risk resistance and future financing capabilities [4].

Core Viewpoint - The company, Anglikang, is facing significant challenges as it plans to raise 1.16 billion yuan through a private placement of A-shares to fund innovative drug research and industrialization projects, amidst a sharp decline in its gross margin from 64.7% in 2021 to 38.78% in the first three quarters of 2025, marking a ten-year low [1][2]. Group 1: Financial Performance - The gross margin of the company has decreased by nearly 40% over four years, raising scrutiny over its financing motives [1]. - The core product's price drop is a major reason for the expected revenue decline in 2024 [1]. Group 2: Financing History - The company has faced ongoing criticism for its "heavy financing and light returns" approach, with previous fundraising efforts resulting in a significant portion of the capital remaining unutilized for intended projects [2]. - As of September 2025, 22.91% of the funds raised in previous rounds had not been invested in the original projects, with 420 million yuan used multiple times to supplement working capital [2]. Group 3: Innovation and Market Position - The new fundraising project is closely related to previous initiatives, with 677 million yuan allocated for "tumor innovative drug research," raising questions about the efficiency of past investments [2]. - The company’s only innovative drug in development, ALK-N001, faces stiff competition in a market with many players already established in the ALK inhibitor space [2]. Group 4: Risks and Investor Concerns - The controlling shareholder has a high equity pledge ratio of 41.81%, which could lead to structural instability if margin calls are triggered [2]. - The dilution of earnings per share from 0.39 yuan to 0.36 yuan post-placement raises concerns for small investors, especially if the innovative drug development fails [2]. - Historical data shows an average stock price decline of 18% within 30 days following the announcement of similar fundraising plans, leaving uncertainty about the current situation [2]. Group 5: Conclusion - The fundraising initiative is viewed as a critical gamble for the company's survival, as the traditional pharmaceutical sector faces challenges from price cuts, pushing the company towards innovative drug development, which is fraught with high failure rates and long investment horizons [3].

Group 1 - Runjian Co., Ltd. is planning to issue H-shares and list on the Hong Kong Stock Exchange [1] - Zhongfu Shenying's shareholder plans to reduce its stake by no more than 1% [2] - Chenxi Aviation's controlling shareholder intends to reduce its stake by up to 3% [2] Group 2 - Zhiguang Electric's subsidiary signed a sales contract worth 152 million yuan [3] - Sanrenxing's controlling shareholder and actual controller plan to transfer up to 8% of the company's shares [4] - Guosheng Technology intends to acquire 100% equity of Fuyue Technology for 241 million yuan [5] Group 3 - Luxiao Technology's controlling shareholder plans to reduce its stake by no more than 3% [7] - Fusenmei's vice president and board secretary are under investigation [8] - Zhongchuang Co., Ltd. plans to transfer 2% of its shares through inquiry [10] Group 4 - Anglikang plans to raise 1.16 billion yuan for innovative drug research and industrialization projects [12] - Shenling Environment intends to issue convertible bonds to raise no more than 1 billion yuan [14] - Songcheng Performing Arts plans to acquire 100% equity of Hangzhou Songcheng Industrial for 963 million yuan [16] Group 5 - Demingli plans to raise no more than 3.2 billion yuan for SSD and DRAM expansion projects [17] - Ziyan Food's three shareholders plan to reduce their stake by no more than 276,700 shares [18] - Xinhua Pharmaceutical received a drug registration certificate for a new product [20] Group 6 - Chunqiu Electronics plans to acquire all shares of Danish liquid cooling technology company Asetek A/S for up to 547 million Danish kroner [22] - Tiandi Digital intends to transfer 100% equity of its subsidiary for 49 million yuan [24] - Huaru Technology plans to invest 20 million yuan to establish a fund focusing on new digital technologies [25] Group 7 - *ST Dongtong's stock may be suspended due to regulatory penalties for false reporting [26] - Siryipu is planning to acquire shares of Ningbo Aola Semiconductor and will suspend trading [27] - Purang Co., Ltd. is planning to acquire 49% equity of Noah Changtian and will suspend trading [29] Group 8 - *ST Suwu is facing potential delisting due to significant violations in financial reporting [32]

Core Viewpoint - The company, Anglikang, plans to raise 116 million yuan through a private placement of A-shares to fund its innovative drug research and industrialization projects [1][3]. Fundraising Details - The total investment for the innovative drug research and industrialization project is 119.56 million yuan, with the company intending to use 116 million yuan from the raised funds [3]. - The issuance will be priced at no less than 80% of the average stock price over the 20 trading days prior to the issuance date [4]. - The number of shares to be issued will not exceed 30% of the total shares before the issuance, amounting to a maximum of 60,518,455 shares [4]. Shareholder Structure - The issuance will involve up to 35 qualified investors, including securities investment funds, securities companies, and qualified foreign institutional investors [4]. - After the issuance, the controlling shareholder, Shengzhou JunTai, will hold 27.26% of the company, while the actual controllers, Fang Nanping and Lü Huizao, will hold 4.25% and 2.77% respectively, leading to a diluted control of 34.27% [5]. Financial Performance - In 2024, the company reported a revenue of 1.54 billion yuan, a decrease of 5.41% year-on-year, and a net profit attributable to shareholders of 80.33 million yuan, down 41.94% [8][9]. - For the first three quarters of 2025, the company achieved a revenue of 1.06 billion yuan, a decline of 5.92%, but the net profit attributable to shareholders increased by 55.59% to 78 million yuan [9][10].

Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - For the period from January to September 2025, Angli康 reported a revenue of 1.055 billion yuan, a year-on-year decrease of 5.92%. However, the net profit attributable to shareholders increased by 55.59% to 77.6899 million yuan [2]. - The company has distributed a total of 360 million yuan in dividends since its A-share listing, with 128 million yuan distributed over the past three years [3]. Stock Performance - As of November 26, Angli康's stock price increased by 2.04% to 40.60 yuan per share, with a total market capitalization of 8.19 billion yuan. The stock has risen by 213.25% year-to-date, although it has seen a decline of 0.55% over the last five trading days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) 15 times this year, with the most recent appearance on October 21, where it recorded a net buy of 15.2289 million yuan [1]. Shareholder Structure - As of September 30, 2025, Angli康 had 28,500 shareholders, an increase of 54.58% from the previous period. The average number of circulating shares per shareholder decreased by 35.31% to 6,493 shares [2]. - Notable institutional shareholders include 广发医疗保健股票A, 中欧医疗健康混合A, and several new entrants such as 汇添富创新医药混合A and 长城医药产业精选混合发起式A [3]. Industry Classification - Angli康 operates within the pharmaceutical and biotechnology sector, specifically in the chemical pharmaceutical and chemical formulation sub-industry. The company is associated with various concepts, including ursodeoxycholic acid, Helicobacter pylori, pet economy, hypertension prevention, and vitamins [2].